Hiltonol

Generic Name: Hiltonol

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 59789-29-6

Unique Ingredient Identifier: 7KYP9TKT70

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in the HVTN706/MOSAICO Study and Remain Without HIV

Phase 1

Not yet recruiting

Conditions: HIV Infections

Interventions: Biological: Hiltonol

First Posted Date: 2024-10-30

Last Posted Date: 2024-10-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT06665646

Locations: 🇵🇪
Lima - San Marcos, Bella Vista, Peru
🇵🇪
Iquitos (ACSA CRS), Iquitos, Peru
🇵🇪
Lima - Via Libre, Lima, Peru

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Phase 1

Not yet recruiting

Conditions: Muscle-Invasive Bladder Carcinoma

Interventions: Biological: Synthetic long peptide personalized cancer vaccine
Drug: Poly ICLC
Biological: Nivolumab
Device: Signatera assay

First Posted Date: 2024-07-31

Last Posted Date: 2024-07-31

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 16

Registration Number: NCT06529822

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma

Phase 1

Recruiting

Conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant

Interventions: Procedure: Biospecimen Collection
Biological: Dendritic Cell Therapy
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Drug: Poly ICLC

First Posted Date: 2024-04-02

Last Posted Date: 2024-12-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 6

Registration Number: NCT06342908

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC

Phase 1

Not yet recruiting

Conditions: Stage IV NSCLC

Interventions: Drug: Poly ICLC
Drug: IVIG

First Posted Date: 2023-10-03

Last Posted Date: 2024-04-30

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 16

Registration Number: NCT06064279

Locations: 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

Phase 1

Not yet recruiting

Conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Biological: Dendritic Cell Tumor Peptide Vaccine
Procedure: Leukapheresis
Drug: Placebo Administration
Drug: Poly ICLC
Procedure: Resection

First Posted Date: 2022-07-14

Last Posted Date: 2024-06-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 15

Registration Number: NCT05457959

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM

Phase 1

Recruiting

Conditions: Glioma, Malignant

Interventions: Biological: Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine
Drug: Hiltonol

First Posted Date: 2022-03-16

Last Posted Date: 2024-08-23

Lead Sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP

Target Recruit Count: 36

Registration Number: NCT05283109

Locations: 🇺🇸
The Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States

A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Poly ICLC

First Posted Date: 2022-03-16

Last Posted Date: 2022-03-16

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 10

Registration Number: NCT05281926

Locations: 🇨🇳
NTUH, Taipei City, Zhongzheng Dist, Taiwan

Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery

Phase 1

Recruiting

Conditions: Pancreas Cancer
Pancreatic Cancer
Cancer of the Pancreas

Interventions: Biological: Optimized neoantigen synthetic long peptide vaccine
Biological: Poly-ICLC

First Posted Date: 2021-11-08

Last Posted Date: 2024-12-11

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 34

Registration Number: NCT05111353

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer

First Posted Date: 2021-10-28

Last Posted Date: 2024-10-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05098210

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm

Phase 1

Recruiting

Conditions: Myelofibrosis
Essential Thrombocythemia
MPN

Interventions: Drug: Peptide-based vaccine
Drug: Poly ICLC

First Posted Date: 2021-08-27

Last Posted Date: 2024-03-15

Lead Sponsor: Marina Kremyanskaya

Target Recruit Count: 10

Registration Number: NCT05025488

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy